Valuation: Appili Therapeutics Inc.

Market Cap 7L 5L 4L 4L 4L 4.48Cr 7L 46.82L 18.59L 2.35Cr 17.69L 17.31L 7.44Cr P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 1.36Cr 96.53L 86.64L 80L 72.54L 92Cr 1.37Cr 9.59Cr 3.81Cr 48Cr 3.62Cr 3.55Cr 152.41Cr EV / Sales 2025
15,24,29,607x
EV / Sales 2026 6,09,46,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
05/10 Appili Therapeutics Inc. Primary Exchange Listing will Change to TSX Venture Exchange from The Toronto Stock Exchange CI
05/10 Appili Therapeutics Inc. will Change its Ticker to APLI.H from APLI CI
15/08 Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
04/07 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
27/06 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
27/06 Appili Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
18/02 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
13/02 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
18/12 Appili Therapeutics closes first tranche of non-brokered private placement RE
15/12 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
14/11 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
14/11 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
14/11 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
1 day+100.00%
3 months-33.33%
6 months-33.33%
Current year-60.00%
1 week 0
Extreme 0.005
0.01
1 month 0
Extreme 0.005
0.02
Current year 0
Extreme 0.005
0.02
1 year 0
Extreme 0.005
0.03
3 years 0
Extreme 0.005
0.06
5 years 0
Extreme 0.005
0.78
10 years 0
Extreme 0.005
1.89
Manager TitleAgeSince
Chief Executive Officer 65 01/11/2022
Director of Finance/CFO 68 16/11/2021
Corporate Officer/Principal - 01/10/2022
Director TitleAgeSince
Director/Board Member 70 27/01/2020
Director/Board Member 62 13/11/2023
Chairman 50 07/05/2015
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/26 Option

Chief Executive Officer

75,000 0.0584%
01/07/26 Option

Chief Financial Officer

1,00,000 0.0779%
01/07/26 Option

Director

1,00,000 0.0779%
Change 5-day change 1-year change 3-year change Capi.($)
+100.00%0.00%-66.67%-71.43% 5L
+0.65%-3.56%+33.53%+60.50% 6.35TCr
+1.76%+1.27%+11.82%+82.12% 5.45TCr
-1.09%+0.80%+10.24%+101.80% 5.36TCr
+1.76%+0.05%+26.89%+56.23% 4.48TCr
+2.11%-3.19%+18.08%+100.50% 4.16TCr
+0.09%-4.01%+220.59%+916.29% 3.99TCr
+0.64%-3.85%+11.71%+45.57% 3.25TCr
+29.06%+47.63%+107.12%+94.27% 2.67TCr
+3.72%-7.45%+24.25%-2.99% 2.34TCr
Average +13.87%-0.38%+39.76%+138.29% 3.8TCr
Weighted average by Cap. +2.98%-0.29%+47.02%+160.28%

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.79 0.1 0.71 0.28 3.56 0.27 0.26 11.29 0.24 0.17 0.16 0.14 0.13 16.51 0.25 1.73 0.69 8.66 0.65 0.64 27.45
Net income -26.25L -18.69L -16.77L -15.49L -14.04L -18Cr -26.57L -1.86Cr -73.74L -9.3Cr -70.15L -68.65L -30Cr -42.41L -30.19L -27.1L -25.02L -22.69L -29Cr -42.93L -3Cr -1.19Cr -15Cr -1.13Cr -1.11Cr -48Cr
Net Debt 1.11Cr 78.79L 70.71L 65.29L 59.21L 75Cr 1.12Cr 7.83Cr 3.11Cr 39Cr 2.96Cr 2.89Cr 124.39Cr 1.29Cr 91.82L 82.41L 76.09L 69L 87Cr 1.31Cr 9.12Cr 3.62Cr 46Cr 3.45Cr 3.37Cr 144.97Cr
Projected Income Statement - Annual - Appili Therapeutics Inc.
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
28/26/28 CA$0.0100 +100.00% 1,250
27/26/27 CA$0.005000 0.00% 2,120
26/26/26 CA$0.005000 -50.00% 7,422
23/26/23 CA$0.0100 +100.00% 1,500
22/26/22 CA$0.005000 -50.00% 18,350
  1. Stock Market
  2. Stocks
  3. APLI.H Stock